检索
AI 对话
analysis
趋势分析
编组
开放平台
more
更多
排名必读论文期刊顶会热点AI 简史溯源树小脉星探人才迁徙塔尖人才国防情报追踪开源工具智慧手语
VIPCreated with Sketch.

BMS-986158, a Potent Bromodomain and Extraterminal Domain Inhibitor (BETi), as Monotherapy and in Combination With Ruxolitinib (RUX) or Fedratinib (FED) in Intermediate-Risk or High-Risk Myelofibrosis (MF): Results From a Phase I/II Study

Rosa Ayala,Nieves Lopez,Adi Shacham Abulafia, Maan Alwan,Costas K. Yannakou,Indu Raman,Vincent Ribrag,Chun Yew Fong,Yulia Volchek,Massimiliano Bonifacio,Alessandra Tucci,Jesus Maria Hernandez Rivas,Blanca Xicoy,Haifa Al-Ali,Jean-Christope Ianotto, Si Tuen Lee-Hoeflich, Sharmilla Das, Bin Wu, Palanikumar Ravindran, Qian Zhao, Guan Wang,Oriana Esposito, Yu Liu,Zariana Nikolova,Christopher Tehlirian,Shodeinde Coker,David Lavie

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA（2023）

引用 0|浏览11
暂无评分
关键词
MPN,myelofibrosis,BETi,JAKi,ruxolitinib,fedratinib
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要